Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients

Inclusion Criteria

• •The following conditions must be met before a patient may be enrolled in the study.
• •Patients age 18 years of age and older.
• •Disease Criteria. Patients will be eligible:
• •If no clinical evidence of disease is present after diagnosis with stage III or
• •IV disease and completion of primary surgery and chemotherapy, or, if no clinical evidence of disease is present after completion of chemotherapy for a disease recurrence diagnosed after a progression-free interval of at least 2 years, for patients of any initial stage.or primary peritoneal carcinoma.
• •Complete clinical response = no evidence of tumor lesions shown by abdominal CT scan or MRI, chest Xray,and CA 125 level ≤ 35 UI/mL.
• •Time from completion of Chemotherapy will be no more than 6 months from last dose from initial diagnoses.
• •HLA-A2 positive (must be typed by molecular methods; all A2 alleles eligible).
• •Patients with adequate organ function as measured by:
• •Hematopoietic: WBC at least 3000/mm3; platelets at least 100,000/mm3, hemoglobin at least 10.0 g/dL (may be transfused).
• •Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at rest must be ≥50% or within the normal range of the institution. A cardiology clearance will be required for LV ejection fraction \<50%.
• •Hepatic: SGOT within 2x normal range and total bilirubin ≤ 2.0 mg/dL.
• •Renal: Serum creatinine ≤2.0 mg/dL
• •Adequate performance status \> 80% (Karnofsky) or ECOG 0-2
• •Written informed consent conforming to institutional guidelines.
• •Life expectancy \> 6 months and absence of co-existing medical problems which would preclude participation in the judgment of the principal investigator.